Abstract
Background: The Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADASCog) remains the most widely used test of longitudinal cognitive functioning in Alzheimer’s disease (AD) clinical trials. Unlike most neuropsychological tests, the ADAS-Cog source documentation worksheets are not uniform across clinical trials, and vary by document layout, inclusion of administration and/or scoring instructions, and documentation of subtest scoring (e.g., recording correct versus incorrect scores), among other differences. Many ADAS-Cog test administrators (raters) participate in multiple AD trials and switching between different ADAS-Cog worksheets may increase the likelihood of administration and/or scoring mistakes that lessen the reliability of the instrument. An anonymous online survey sought raters’ experiences with ADAS-Cog worksheets and their opinions on the design and content of the worksheets.
Results: Results of the survey indicated preference for structure and standardization of the ADASCog worksheets, which has been considered in the development of a standard ADAS-Cog source document by the Alzheimer’s Disease Cooperative Study (ADCS) Working Group.Keywords: Alzheimer's Disease Assessment Scale (ADAS), Alzheimer’s disease, clinical trials, outcomes, rater, survey.
Current Alzheimer Research
Title:Optimizing ADAS-Cog Worksheets: A Survey of Clinical Trial Rater s’ Perceptions
Volume: 14 Issue: 9
Author(s): Stephen M. Meyer, Kristina A. Bertzos, Magdalena Perez, Donald J. Connor*, Kimberly Schafer and Sarah Walter
Affiliation:
- Consultants in Cognitive and Clinical Trials,United States
Keywords: Alzheimer's Disease Assessment Scale (ADAS), Alzheimer’s disease, clinical trials, outcomes, rater, survey.
Abstract: Background: The Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADASCog) remains the most widely used test of longitudinal cognitive functioning in Alzheimer’s disease (AD) clinical trials. Unlike most neuropsychological tests, the ADAS-Cog source documentation worksheets are not uniform across clinical trials, and vary by document layout, inclusion of administration and/or scoring instructions, and documentation of subtest scoring (e.g., recording correct versus incorrect scores), among other differences. Many ADAS-Cog test administrators (raters) participate in multiple AD trials and switching between different ADAS-Cog worksheets may increase the likelihood of administration and/or scoring mistakes that lessen the reliability of the instrument. An anonymous online survey sought raters’ experiences with ADAS-Cog worksheets and their opinions on the design and content of the worksheets.
Results: Results of the survey indicated preference for structure and standardization of the ADASCog worksheets, which has been considered in the development of a standard ADAS-Cog source document by the Alzheimer’s Disease Cooperative Study (ADCS) Working Group.Export Options
About this article
Cite this article as:
Meyer M. Stephen , Bertzos A. Kristina , Perez Magdalena , Connor J. Donald*, Schafer Kimberly and Walter Sarah , Optimizing ADAS-Cog Worksheets: A Survey of Clinical Trial Rater s’ Perceptions, Current Alzheimer Research 2017; 14 (9) . https://dx.doi.org/10.2174/1567205014666170417122744
DOI https://dx.doi.org/10.2174/1567205014666170417122744 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Influence of Sex Hormones on Pulmonary Vascular Reactivity: Possible Vasodilator Therapies for the Treatment of Pulmonary Hypertension
Current Vascular Pharmacology Ultra-micronized Palmitoylethanolamide: An Efficacious Adjuvant Therapy for Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Mass Spectrometry Techniques: Principles and Practices for Quantitative Proteomics
Current Protein & Peptide Science Editorial (Thematic Issue: Current Updates on Association Between Alzheimer’s Disease and Type 2 Diabetes Mellitus - Volume II)
CNS & Neurological Disorders - Drug Targets Pain Experience in Dementia Subtypes: A Systematic Review
Current Alzheimer Research Prospective Function of Different Antioxidant Containing Natural Products in the Treatment of Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Simvastatin is Protective During Staphylococcus aureus Pneumonia
Current Pharmaceutical Biotechnology Adult Neurogenesis, Neural Stem Cells and Alzheimers Disease: Developments, Limitations, Problems and Promises
Current Alzheimer Research The Implications of Autophagy in Alzheimer’s Disease
Current Alzheimer Research Macrophage Colony-Stimulating Factor (M-CSF) in Plasma and CSF of Patients with Mild Cognitive Impairment and Alzheimers Disease
Current Alzheimer Research Blood-Brain Barrier Changes in High Altitude
CNS & Neurological Disorders - Drug Targets Prevalence of Neuropsychiatric Symptoms in Mild Cognitive Impairment and Alzheimers Disease, and its Relationship with Cognitive Impairment
Current Alzheimer Research The Role of 5-Hydroxytryptamine in the Pathophysiology of Migraine and its Relevance to the Design of Novel Treatments
Mini-Reviews in Medicinal Chemistry Nitric Oxide and Major Depressive Disorder: Pathophysiology and Treatment Implications
Current Molecular Medicine Patient-Specific Modeling and Multi-Scale Blood Simulation for Computational Hemodynamic Study on the Human Cerebrovascular System
Current Pharmaceutical Biotechnology Relationship Between the Japanese Version of the Montreal Cognitive Assessment and PET Imaging in Subjects with Mild Cognitive Impairment
Current Alzheimer Research Dehydroevodiamine•HCl Protects Against Memory Impairment and Cerebral Amyloid-β Production in Tg2576 Mice by Acting as a β-Secretase Inhibitor
CNS & Neurological Disorders - Drug Targets The Novel Multi-Target Iron Chelator, M30 Modulates HIF-1α-Related Glycolytic Genes and Insulin Signaling Pathway in the Frontal Cortex of APP/PS1 Alzheimer’s Disease Mice
Current Alzheimer Research Prolyl-Specific Peptidases and Their Inhibitors in Biological Processes
Current Chemical Biology Substance P in Rheumatic Diseases
Current Rheumatology Reviews